(MENAFN- Gulf Times) Hamad Medical Corporation (HMC) is expanding and enhancing its services to improve bone health and reduce the impact of osteoporosis through specialist clinics, early diagnosis and comprehensive treatment options across its facilities.
Affecting around 30% of women and 10% of men over the age of 50, osteoporosis leads to a reduction in bone density and strength, increasing the risk of fractures, mainly in the hips, spine, and wrists. Osteoporosis is often referred to as a silent disease, with many people unaware of the condition until experiencing a fracture. HMC continues to focus its efforts on raising awareness, promoting early diagnosis and prevention, and providing timely and effective care for those at risk.
HMC offers a full range of specialist services that support patients through every stage of osteoporosis management. Dedicated osteoporosis clinics operate across several HMC facilities, providing individualised assessment and care for patients at risk of or living with osteoporosis. Advanced diagnostic tools, including dual-energy X-ray absorptiometry scanning with Vertebral Fracture Assessment and Trabecular Bone Score are available to enable accurate and early diagnosis.
In addition, a specialist Fracture Liaison Clinic at the Bone and Joint Center ensures co-ordinated care for patients recovering from fractures and works to prevent future injuries. A full selection of approved osteoporosis medications - oral, subcutaneous, and intravenous - are available and prescribed based on each patient's clinical needs. HMC encourages members of the public, especially those with risk factors such as age, menopause, or family history of fractures, to speak with their family physician about screening for osteoporosis, while regularly exercising and eating a diet rich in calcium and vitamin D to help strengthen bones. The FRAX online tool is used by healthcare teams and patients to predict the 10-year risk of fractures caused by osteoporosis.
This electronic system calculates and tracks key factors that should be considered when managing osteoporosis, enabling treatment decisions to be based on fracture risk assessment rather than bone density measurements alone Medical Corporation osteoporosis

MENAFN03112025000067011011ID1110290079